No segmentation disclosed for this filer. n/a
Rafarma Pharmaceuticals, Inc. booked $9.2M in FY2025 revenue, growing 1.1% year over year — about the middle of the pack among Healthcare companies we track, at a 3.8% net margin.
No filings loaded — no CIK (non-SEC filer).